Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma
Go back to Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma| (NASDAQ: ALLO) | Delayed: 2.10 +0.10 (5.00%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.00 | 52 Week High | $ | |||
| Open | $2.03 | 52 Week Low | $ | |||
| Day High | $2.18 | P/E | N/A | |||
| Day Low | $2.01 | EPS | $ | |||
| Volume | 6,571,889 | |||||
| (NASDAQ: NTRA) | Delayed: 228.80 -2.61 (1.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $231.41 | 52 Week High | $13.80 | |||
| Open | $231.52 | 52 Week Low | $6.52 | |||
| Day High | $234.14 | P/E | N/A | |||
| Day Low | $219.50 | EPS | $0.00 | |||
| Volume | 1,577,833 | |||||
